Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. For patients with early-stage disease, surgery followed by adjuvant chemotherapy is the optimal treatment. For patients with locally advanced disease, the standard approach is chemoradiotherapy, since it offers a small but statistically significant prolongation in survival compared with the sequential approach. It should be noted, however, that this approach is associated with significant toxicity and it only applies to patients with good performance status. For patients with metastatic disease, chemotherapy represents the cornerstone of treatment and results in a median survival of approximately 10 months. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel ‘targeted agents’ and will further improve outcomes for these patients.
Share this Article
Related Content In Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options
Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95
Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as pain and dysphagia, which can negatively impact patient quality of life.1 Severe esophagitis requires parenteral […]
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!